Micropapillary bladder cancer: Current treatment patterns and review of the literature by Willis, Daniel L. et al.
Micropapillary Bladder Cancer: Current Treatment Patterns and 
Review of the Literature
Daniel L. Willis, MD,
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Thomas W. Flaig, MD,
Division of Medical Oncology, University of Colorado Denver, School of Medicine, Denver, 
Colorado
Donna E. Hansel, MD, PhD,
Department of Pathology, UC San Diego, School of Medicine, San Diego, California
Matthew I. Milowsky, MD,
Division of Hematology/Oncology, University of North Carolina, School of Medicine, Chapel Hill, 
North Carolina
Robert L. Grubb, MD,
Division of Urologic Surgery, Washington University School of Medicine in St. Louis, St. Louis, 
Missouri
Hikmat A. Al-Ahmadie, MD,
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York City, New York
Elizabeth R. Plimack, MD, MS,
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania
Theresa M. Koppie, MD,
Department of Urology, Oregon Health and Science University, Portland, Oregon
David J. McConkey, PhD,
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Colin P. Dinney,
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Vanessa A. Hoffman, MPH,
Bladder Cancer Advocacy Network, Bethesda, Maryland
Michael J. Droller, MD,
Department of Urology, Mount Sinai Hospital, New York City, New York
Corresponding author: Ashish M. Kamat, Department of Urology, Unit 1373, The University of Texas MD Anderson Cancer Center, 
1515 Holcombe Boulevard, Houston, TX 77030, USA Telephone: 713-792-3250; Fax: 713-794-4824; akamat@mdanderson.org. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Urol Oncol. Author manuscript; available in PMC 2015 December 22.
Published in final edited form as:













Edward Messing, MD, and
Department of Urology, University of Rochester Medical Center, School of Medicine and 
Dentistry, Rochester, New York
Ashish M Kamat, MD
Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Abstract
Objectives—No guidelines exist for management of micropapillary bladder cancer (MPBC) and 
the majority of reports of this variant of urothelial carcinoma (UC) are case series comprised of 
small numbers of patients. We sought to determine current practice patterns for MPBC using a 
survey sent to the Society of Urologic Oncology (SUO) and to present those results in the setting 
of a comprehensive review of the existing literature.
Materials and Methods—A survey developed by the Translational Science Working Group of 
the Bladder Cancer Advocacy Network sponsored Think Tank meeting was distributed to 
members of the SUO. The results from 118 respondents were analyzed and presented with a 
literature review.
Results—The majority of survey respondents were urologists with 80% considering bladder 
cancer their primary area of interest. Although 78% of the respondents reported a dedicated 
genitourinary pathologist at their institution, there were discrepant opinions on how a pathologic 
diagnosis of MPBC is determined as well as variability on the proportion of MPBC that is 
clinically significant. 78% treat MPBC differently than conventional UC with 81% reporting that 
they would treat cT1 MPBC with upfront radical cystectomy. However, the respondents were split 
regarding the sensitivity of MPBC to cisplatin-based chemotherapy which affected utilization of 
neoadjuvant chemotherapy in muscle invasive disease.
Conclusions—The management of MPBC is diverse among members of the SUO. While the 
majority favors early cystectomy for cT1 MPBC, there is no consensus on the use of neoadjuvant 
chemotherapy for muscle-invasive MPBC.
Keywords
micropapillary; bladder cancer; review; survey
Introduction
Micropapillary bladder cancer (MPBC) was first reported in 1994 [1] and is listed under the 
most recent WHO classification as a variant form of infiltrating urothelial carcinoma (UC). 
Micropapillary morphology exists in several other organ sites, namely lung, breast, and 
gastrointestinal tract, and seems to display aggressive behavior regardless of tissue of origin 
[2]. The biology of MPBC is poorly understood. While it is most commonly detected in a 
background of conventional UC, it can also be associated with squamous cell carcinoma [3], 
adenocarcinoma [4], small cell carcinoma [5], and sarcomatoid carcinoma [6]. MPBC is also 
unique in that clinical significance has been associated with even a small amount of 
micropapillary histology relative to conventional UC (>10%) [7].
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Early reports of micropapillary bladder cancer demonstrated an association with locally 
advanced and metastatic disease [1,3-5,7]. In the largest retrospective report of MPBC to 
date by Kamat et al (n=100) from MD Anderson Cancer Center, the overall prognosis of 
patients with MPBC was poor despite the inclusion of a large proportion of patients with 
non-muscle invasive (NMI) micropapillary disease. NMI-MPBC demonstrated a poor 
response to BCG and the authors advocated for early cystectomy for organ confined disease 
[8,9]. Concern was also raised related to a potential poor response to neoadjuvant 
chemotherapy (NAC). While several series have demonstrated similar findings [10,11], 
other smaller single-institution studies have suggested that outcomes may be comparable for 
MPBC and conventional UC after controlling for stage [12,13]. Others have also suggested 
that the use of neoadjuvant chemotherapy [10,14] and BCG may be appropriate in MPBC.
[15]
Given the limitations of the current literature for MPBC, physicians often base management 
on personal experience and expert opinion. To better understand MPBC, the Translational 
Science Working Group of the Bladder Cancer Advocacy Network (BCAN) Bladder Cancer 
Think Tank meeting [16] established a multi-institutional collaborative effort to study 
MPBC to provide improved insights into the biology and management of this disease. As an 
initial step, a survey was sent to the members of the Society of Urologic Oncology to 
determine current opinions and practice patterns for MPBC. The results of the survey are 
presented herein in the context of a comprehensive review of existing literature.
Materials and Methods
The MPBC survey was designed based on input and review from the Translational Science 
Working Group of the BCAN sponsored Bladder Cancer Think Tank and distributed among 
registered members (n=632) of the Society of Urologic Oncology (SUO) using 
SurveyMonkey Inc. (Palo Alto, CA, USA) [17]. SurveyMonkey was used to collect and 
analyze the results of the survey. A total of 130 responses were recorded, providing a 
response rate of 20%; of these, 91% (n=118) completed the entire survey.
A review of the literature was performed for all original articles published before July 1, 
2013 by incorporating the following terms in a Medline database search: micropapillary and 
bladder cancer. All articles were reviewed for relevance and sample size for inclusion in the 
review.
Results
Table 1 summarizes the composition of the 118 responders who completed the survey. 94% 
were urologists, 5% were medical oncologists, and 1% were pathologists. A majority (80%) 
of the survey population considered bladder cancer their primary practice focus with 49% 
reporting that bladder cancer occupies 25-50% of their practice. 65% reported managing 1-5 
cases of MPBC in the last year, while 16% did not treat MPBC in the last year.
Table 2 summarizes the respondents opinions related to MPBC. While 78% of the survey 
population reported an affiliation with a dedicated genitourinary pathologist, only 49% 
responded that the diagnosis of MPBC utilizes strict, reproducible pathologic criteria. 51% 
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reported that the diagnosis of MPBC is based on variable pathologic diagnostic criteria. 95% 
reported that MPBC represents a subtype/variant of urothelial carcinoma. 20% responded 
that micropapillary histology was clinically irrelevant if it is reported as “focal,” while the 
majority felt that the mere presence of micropapillary architecture is clinically relevant 
(75%). A few members of the survey (4%) further clarified that they considered MPBC as 
clinically irrelevant if it represented <5-25% of the specimen. 78% treat MPBC differently 
than conventional UC, while 13% reported that it depends on the percentage of MPBC in the 
TUR specimen. 9.5% reported that they treat MPBC the same as conventional UC.
Stage specific practice patterns for MPBC are summarized in Table 3. For cTa MPBC, 28% 
advocated early radical cystectomy, 36% advocated intravesical BCG, while 22% favored 
TUR alone followed by observation. In contrast, 81% preferred upfront radical cystectomy 
for cT1 MPBC; (8% would recommend neoadjuvant chemotherapy in addition to 
cystectomy). 11% report that they would treat cT1 MPBC with intravesical BCG.
For muscle-invasive MPBC, 50% would recommend neoadjuvant cisplatin-based 
chemotherapy for cT2 MPBC. 48% would recommend early radical cystectomy with 
adjuvant chemotherapy based on pathology. Additionally, 12% reserved neoadjuvant 
chemotherapy only for those with high risk features such as lymphovascular invasion or 
hydronephrosis. For locally advanced MPBC (cT3-cT4a), the majority responded that they 
would treat with preoperative chemotherapy followed by consolidative surgery (63%). 28% 
would still advocate early cystectomy followed by adjuvant chemotherapy based on 
pathology while only 5% would use primary chemotherapy. In patients with MPBC who 
have lymph node metastasis at radical cystectomy, 26% report that the micropapillary 
component represented the dominant histology of the metastatic tumor, while 10% report 
lymph nodes that are composed primarily of non-micropapillary tumor. 64% reported that 
they did not know the makeup of lymph node metastasis in MPBC.
Discussion and Review of Literature
The results of this web-based survey reflect the current state of opinions and management of 
MPBC by practitioners focused on bladder cancer. In the discussion, we attempt to place 
these results in the context of existing data on this variant histology.
Diagnosis
While there was consensus on the definition of MPBC as a subtype/variant of UC, there 
were different opinions on the pathologic diagnosis of MIBC with approximately half of 
respondents reporting that pathologists use strict, reproducible criteria with the other half 
reporting variability in diagnostic criteria; although this is largely based on the impression of 
respondents on the criteria that pathologist employ for diagnosis. This highlights one 
potential problem in interpreting the existing literature on MPBC which involves the 
reliability and accuracy of the pathologic diagnosis of MPBC variant histology. This 
difficulty in diagnosis may be partially the result of sampling error and tumor heterogeneity 
as TUR specimens have been reported to detect only 39% of variant histology [18,19].
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MPBC classically shows small, tight clusters of neoplastic cells generally devoid of 
fibrovascular cores and arranged in clear lacunar spaces. This key feature of prominent 
retraction artifact surrounding these epithelial nests can mimic angiolymphatic invasion by 
the tumor and can make interpretation difficult. The neoplastic cells often demonstrate 
eosinophilic cytoplasm and nuclear polarization to the external surface of the micropapillary 
clusters. Vesicular nuclei, marked atypia, prominent nucleoli and variable mitotic activity 
may also be present [2]. True angiolymphatic invasion is identified in the majority of cases 
and is typically found peripheral to the primary tumor mass [1].
An enlightening study by Sangoi and colleagues in 2010 further demonstrates why 
comparison between MPBC studies may be difficult. In this report, 14 genitourinary 
subspecialist pathologists reviewed representative H&E images of 30 cases initially 
identified as invasive micropapillary bladder cancer in an attempt to evaluate diagnostic 
variation among pathologists for MPBC. While 93% agreement was obtained among 10 
cases of “classic” MPBC, the overall inter-observer agreement was only moderate for the 
remaining 20 cases whose morphologic features were not classic for MPBC as a result of 
inconsistent interpretations of extensive retraction and varying sized tumor nests (kappa of 
0.54) [20]. Furthermore, there may be a general lack of awareness of MPBC based on 
additional reports suggesting that variant histology may be missed or under-reported in up to 
44% of cases, particularly outside of academic institutions [21]. Unfortunately, further 
attempts to identify reliable immunohistochemical markers for MPBC to improve diagnosis 
have also proven unsuccessful because of low specificity and sensitivity [22.23].
A separate pathology-based question that has been raised in the management of MPBC 
involves the clinical significance of MPBC in mixed tumors? Based on the survey, 
approximately 75% of physicians reported that any amount of MPBC is clinically 
significant. In contrast, 20% felt that focal MPBC was clinically irrelevant. While limited by 
small sample sizes, a correlation between increasing proportion of MPBC and worse 
prognosis has been reported [7,24]. Alvarado-Cabrero reported that patients with >50% 
MPBC have a relative mortality risk of 2.4 compared with conventional UC patients while 
patients with < 50% were at similar risk. In a separate study, a 10% cutoff was reported as a 
clinically significant effect on disease specific survival [7] that has led to the reporting of 
even focal amounts of MPBC. However, many conflicting reports exist ranging from those 
stating that the mere presence of MPBC is clinically relevant [11] to others stating that focal 
MPBC portends better outcomes than extensive disease [15,24]. A large scale, detailed 
analysis of the effect of extent of micropapillary histology and clinical outcomes is lacking. 
Determining the clinical significance of the extent of MPBC may be an important guide to 
direct clinical management of MPBC and represents an important future area of 
collaboration between clinicians and pathologist.
Treatment
The vast majority of experts (77%) agree that MPBC should be treated differently than 
conventional UC. However, there is significant variability about how the disease should be 
treated within each pathological stage.
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The greatest consistency appears to be in the management of cT1 tumors as most 
respondents recommend early radical cystectomy. This approach to the management of non-
muscle invasive MPBC (NMI-MPBC) was first suggested by MD Anderson in 2006 based 
on one of the largest cohorts of MPBC reported to date [8]. In that analysis, the NMI-MPBC 
cohort included 44 patients (11% Ta, 9% CIS, 80% cT1, n=44) treated with intravesical 
BCG or upfront radical cystectomy. Among patients treated initially with BCG therapy, 
67% progressed (defined as ≥cT2) including 22% in whom metastases developed. Only 19% 
of the primary BCG cohort remained disease-free with an intact bladder after a median 
follow-up of 30 months. Among patients who underwent cystectomy after progression, 
median cancer specific survival (CSS) was 61.7 months with no patients surviving at 10 
years. In contrast, those patients receiving upfront cystectomy had a 10-year CSS rate of 
72% and median survival was not reached. These poor response rates to BCG led to the 
author's recommendation for early cystectomy. This study also reported a 42% rate of 
pathologic upstaging in the upfront cystectomy patients (n=12), including a 25% rate of 
occult nodal disease, which raises concern for clinical understaging for NMI-MPBC.
Other smaller retrospective series that contain patients with NMI-MPBC have been reported. 
Ghoneim et al reported 10 patients diagnosed with cTis-cT1 disease, of whom 7 received 
intravesical BCG and 3 underwent upfront radical cystectomy [10]. All 7 patients treated 
with BCG recurred (4 progressed) and underwent delayed radical cystectomy with resultant 
pT3 disease. Furthermore, positive lymph nodes were detected in 6 patients. Comperat et al 
reported on a 72 patient cohort of MPBC including 12 cTa MPBC cases, of which 8 were 
treated with radical cystectomy [11]. All 8 were found to have invasive carcinoma at the 
time of surgery including 5 (63%) with pT2-pT4 disease. A recent 120 patient SEER 17-
based study also showed that NMI-MPBC was associated with worse overall and disease 
specific survival outcomes in a population based study when compared to conventional UC 
[25]. These studies all suggest that NMI-MPBC is associated with more aggressive disease 
and worse survival than would be expected for conventional NMIBC and may warrant more 
aggressive intervention.
Another study argues that NMI-MBPC may have a different histologic presentation than 
muscle-invasive MPBC (MI-MPBC) as the authors suggest that true NMI-MPBC is more 
“urothelial” in appearance than the often “glandular” MI-MPBC [26]. Of the 18 patients in 
this report, treatment data was available on 13: 7 (54%) underwent primary intravesical 
therapy, 5 (38%) underwent initial surveillance only, and 1 (8%) underwent primary 
surgery. Three patients progressed to muscle invasion (pT2, pT3, pT3N2). One patient died 
of bladder cancer, one died of other causes, and 64% are alive with an intact bladder after a 
median follow up of 14 months. In a report by Gaya et al on 8 patients with NMI-MPBC, 6 
(75%) patients (small proportion of MPBC relative to conventional UC) were reported to be 
disease free after BCG therapy with a 5-year DSS of 87.5% [15]. Despite the limited sample 
size, this report has been cited to suggest that BCG may be appropriate for NMI-MPBC.
Overall, the data suggest that the biology of NMI-MPBC is different than conventional UC 
and is associated with an aggressive phenotype with high failure rates of intravesical 
therapy. This viewpoint is consistent with the opinion of the respondents to this survey with 
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80.5% advocating for early cystectomy (7.6% with neoadjuvant chemotherapy) for cT1 
MPBC representing one of the few therapeutic approaches with relative consensus. Further 
validation would still be beneficial to establish the proper management approach for NMI-
MPBC.
Muscle invasive MPBC
In contrast to some areas of agreement on the treatment of NMI-MPBC, the survey response 
reflects differences of opinion related to management of MI-MPBC. The differences relate 
predominantly to the sensitivity of MPBC to chemotherapy and whether it should be 
incorporated in the neoadjuvant setting. Thus, for cT2 MPBC, no consensus on the use of 
perioperative chemotherapy was seen, with 47.5% of respondents recommending early 
radical cystectomy with adjuvant chemotherapy and 50% recommending neoadjuvant 
chemotherapy followed by radical cystectomy. Interestingly, a slightly higher proportion 
(63%) recommended neoadjuvant chemotherapy followed by consolidative surgery for 
cT3-4a N0 disease. A review of the MPBC literature for muscle invasive disease 
demonstrates a relatively consistent conclusion that MI-MPBC is associated with high rates 
of locally advanced and distant disease and is associated with poor survival [4,5,7,10,25]. In 
one of the largest series of MPBC (n=100) patients were reported to have poor 5 and 10-year 
survival rates of 54% and 27% respectively, despite a high proportion of NMI-MPBC 
disease at presentation [9]. In this cohort, high rates of upstaging (52.7%) and occult lymph 
node metastases (27.3%) were also reported after cystectomy (n=65 with curative intent). 
This is similar to the French series which reported a 79% rate of upstaging at cystectomy 
(n=57) with metastasis present in 35% [11]. Wang et al reported (n=73) that 66% were 
found to have pT3/4 disease and 50% had pN+ disease (10-year CSS of 31%). However, 
when stage matched with patients with pure UC, micropapillary tumors had similar rates of 
local/distant recurrence and cancer specific survival [12]. Similarly, Fairey et al compared a 
cohort of MPBC (n=33, 82% diagnosed incidentally at cystectomy) to conventional UC and 
also reported similar survival outcomes after controlling for clinical and pathological 
factors. Vourganti et al compared MPBC to conventional UC in a SEER based outcome 
study and found that stage for stage, MPBC had a similar survival profile to conventional 
UC except for in non-muscle invasive disease where NMI-MPBC was associated with worse 
survival [25]. This provides further support for upfront aggressive management of NMI-
MPBC and the fact that accurate staging may be the major prognostic factor for both 
micropapillary and conventional MI-MPBC.
An understanding of the role for chemotherapy is particularly important in MPBC due to its 
association with locally advanced and distant disease. In the survey, 50% believed MPBC 
responded to cisplatin-based chemotherapy regimens while 50% did not. The variability in 
the recommendation for perioperative chemotherapy (i.e. neoadjuvant vs. adjuvant) was also 
an underlying theme for MI-MPBC disease. Kamat et al raised a concern that existing 
conventional UC chemotherapy regimens might not provide a survival advantage to patients 
with MPBC [9]. Despite a downstaging rate of 61% with NAC and a 38% incidence of node 
positive disease with upfront cystectomy (vs. 13% with NAC p=0.065), patients receiving 
NAC plus radical cystectomy (n=23) had a 5-yr OS of 63% and 10-yr OS 32% compared to 
5-yr OS 71% and 10-yr OS 52% with upfront radical cystectomy (n=32). While the 
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neoadjuvant chemotherapy and upfront cystectomy groups were similar in terms of clinical 
staging, they differed in terms of LVI at TUR (47.8% vs. 12.5%, p=0.004 respectively) and 
use of adjuvant chemotherapy (8.7% vs. 53.1%, p=0.002 respectively).
Others have argued that based on the high rates of upstaging and lymph node involvement at 
radical cystectomy, chemotherapy should be incorporated in the neoadjuvant setting. 
Ghoneim et al made this recommendation based on the poor disease specific survival 
associated with 15 patients who received adjuvant chemotherapy in their series [10]. In a 
recent retrospective report from Memorial Sloan-Kettering Cancer Center (MSKCC), Meeks 
et al focused on the use of neoadjuvant chemotherapy in MI-MPBC [14]. The NAC arm 
contained 29 patients, the majority of whom received neoadjuvant gemcitabine-cisplatin 
prior to surgery and this was compared to a cohort of 19 patients who underwent upfront 
radical cystectomy. They reported a pT0 rate of 45% (defined as pT0+CIS) in the NAC 
group compared to 13% in the radical cystectomy alone group (p=0.049), which is similar 
(38% and 15% respectively) to the pT0 rate seen in the neoadjuvant SWOG trial 8710 [27]. 
The MSKCC report showed a significant survival benefit favoring patients who were 
downstaged versus those with residual tumor (2-yr CSS of 78% and 25% respectively, 
p=0.05), though the follow-up was relatively short. To date, all series on neoadjuvant 
chemotherapy are limited by small sample sizes, retrospective studies, selection bias, failure 
to quantify the extent of MPPBC, and poor understanding into the optimal chemotherapy 
strategy for MPBC. However, an encouraging pathologic response has been noted with pre-
operative chemotherapy, but there remains concern regarding OS, particularly in the MD 
Anderson cohort. While the report from Ghoneim et al reports that most patients received 
gemcitabine-cisplatin chemotherapy, the vast majority from the larger MD Anderson cohort 
received Methotrexate-Vinblastine-Adriamycin-Cisplatin (MVAC) chemotherapy; it is 
possible that differences in the chemotherapy regimens may contribute to differences in 
outcome.
In summary, a review of the literature supports the results of our survey, with the conclusion 
that the management of MPBC remains controversial and clearly merits further research. 
One limitation of our report is the specialized subset of physicians made up of 
predominantly academic, urologic oncologists with access to a specialized urologic 
pathologist. A greater sampling of medical oncologists, radiation oncologists, and 
community practitioners may have yielded different results. However, variations in 
management strategies were noted even among this specialized group representing those 
who might have the greatest insight into MPBC. A second limitation of this report is the 
relatively low, 20% survey response rate obtained from the SUO membership. While this 
response rate is not ideal, 20% is an acceptable response rate based on a search of the 
literature which demonstrates similar rates of response from other survey-based studies with 
rates ranging from 6.5-32% among health care providers including nurses, physicians, 
residents, and medical students [28-32]. The present survey may represent a self-selection 
bias as most respondents claimed to have a special interest in bladder cancer and thus 
reflects the proportion of SUO members with expertise in the field. The response rate of 
20% is likely reflective of a core group of bladder cancer experts who have some view on 
the management of micropapillary bladder cancer, which is an uncommon variant and hence 
we would caution the reader that this reflects a selected group of SUO members.
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The most fundamental question pertaining to MPBC is whether this histologic variant 
should be treated differently than conventional UC, and if so, how should the treatment 
algorithm differ? One could argue based on experience with conventional UC that high risk 
features warrant early cystectomy for NMIBC and a multi-modality treatment approach for 
MIBC. However, sensitivity to modalities such as chemotherapy, radiation therapy, and 
intravesical therapy must be adequately established as delaying surgery for ineffective 
therapy may result in worse outcomes for MPBC.
Unfortunately, all available studies on MPBC at this time are retrospective and inadequately 
powered. Furthermore, no clinical studies to date have been performed with centralized 
pathologic review that incorporates validation of MPBC by independent pathologist. As 
previously discussed, the inter-observer variability among even the most experienced 
pathologists is relatively great and potentially confounds all current studies and limits the 
ability to interpret and compare current series. As early pathologic recognition of MPBC is 
likely to increase, there are potential opportunities in the future to improve the study of this 
disease. Future areas of research should center on the development of reproducible 
diagnostic pathologic criteria as well as the creation of appropriately controlled studies to 
allow more definitive guideline creation for MPBC. This will likely require collaborative 
and multi-institutional studies to increase sample size. The Translational Science Working 
Group of the BCAN sponsored Bladder Cancer Think Tank is currently focusing their 
efforts on these and other questions in MPBC using a collaborative model for the study of 
uncommon bladder cancer variants through the creation of a centralized site for pathologic 
review, data collection, and molecular and gene expression profiling with collaborative data 
analysis.
Conclusion
The management of MPBC is diverse among members of the Society of Urologic Oncology. 
While most favor early cystectomy for cT1 MPBC, there is no consensus on the 
incorporation of neoadjuvant chemotherapy with radical cystectomy for MI-MPBC. The 
Translational Science Working Group of the BCAN sponsored Bladder Cancer Think Tank 
is currently focusing their efforts on developing a better understanding of MPBC by pooling 
resources across institutions with the goal to enhance our understanding of this disease and 
to develop evidence based treatment guidelines.
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Table 1
Characteristics of SUO survey respondents
Question Response Percent
Specialty
    Urologist 94.7%
    Medical oncologist 4.5%
    Pathologist 0.8%
    Radiation Oncologist 0%
Practice Experience
    In training 2.5%
    0-5 years in practice 37.3%
    5-20 years in practice 35.6%
    >20 years in practice 24.6%
    Retired 0%
Practice Affiliation
    Academic institution WITH a comprehensive, NCI designated cancer center 61.9%
    Academic institution WITHOUT a comprehensive, NCI designated cancer center 27.1%
    Large group private practice 5.1%
    Small group private practice 5.9%
Percent of clinical practice focusing on bladder cancer
    >75% 7.6%
    50-75% 22.9%
    25-49% 49.2%
    <25% 20.3%
The number of cases of MPBC seen in the last year
    0 15.3%
    1-5 65.3%
    6-10 16.1%
    11-20 0.8%
    >20 2.5%
Proportion reporting a dedicated GU pathologist
    Yes 78%
    No 22%
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Table 2
Survey results regarding opinions toward MPBC
Question Response Percent
Reported opinions on the definition of MPBC
    Subtype/variant of urothelial carcinoma 94.9%
    Form of bladder cancer that is unrelated to urothelial cancer 3.4%
    Systemic entity that can also involve the bladder 0%
    Descriptive term used by pathologists for an entity that does not have clinical relevance 1.7%
Reported opinions on the pathologic diagnosis of MPBC
    Utilizes strict criteria that are reproducible in most cases 49.2%
    Depends on the pathologist as there is a lot of variability in the diagnostic criteria 50.8%
    Is based on the clinical behavior of the lesion as no true pathologic criteria exists 0%
The proportion of MPBC felt to be clinically IRRELEVANT
    It is reported as only focal vs. extensive 20.3%
    I do not think it matters as any quantity of micropapillary histology is clinically relevant 75.4%
    It is reported as less than x%: (5%-25% reported) 4.2%
Proportion treating MPBC the same as conventional UC
    Yes 10.2%
    No 77.1%
    Depends on the percentage of MPBC in the TUR specimen 12.7%
Proportion considering MPBC to respond to BCG
    Yes 5.9%
    No 73.7%
    Not applicable to my practice 20.3%
Proportion considering MPBC to respond to cisplatin-based chemotherapy regimens
    Yes 50.0%
    No 50.0%
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Table 3
Survey results for stage specific management of MPBC
Question Response Percent
Treatment recommendation for cTa stage MPBC
    TUR alone followed by observation 22.0%
    Intravesical BCG 37.3%
    Early radical cystectomy 28.0%
    Neoadjuvant chemotherapy followed by radical cystectomy 0%
    Not applicable to my practice 12.7%
Treatment recommendation for cT1 stage MPBC
    TUR alone followed by observation 1.7%
    Intravesical BCG 11.9%
    Early radical cystectomy 72.9%
    Neoadjuvant chemotherapy followed by radical cystectomy 7.6%
    Radiation therapy (+/− chemotherapy) 0%
    Not applicable to my practice 5.9%
Proportion recommending neoadjuvant chemotherapy for cT2 stage (cN0) MPBC
    Yes 50.0%
    No 34.7%
    Only for high risk feature such as lymphovascular invasion or hydronephrosis 11.9%
    Not applicable to my practice 3.4%
Treatment recommendation for cT2 (cN0) MPBC
    Early radical cystectomy with adjuvant chemotherapy based on pathology report 47.5%
    Neoadjuvant chemotherapy followed by radical cystectomy 50.0%
    TUR alone 0%
    Radiation therapy (+/− chemotherapy) 0%
    Not applicable to my practice 2.5%
Treatment recommendation for cT3-4a stage (cN0) MPBC
    Chemotherapy 5.1%
    Neoadjuvant chemotherapy followed by consolidative surgery 62.7%
    Early radical cystectomy with adjuvant chemotherapy based on pathology report 28.0%
    Palliative care 0%
    Radiation therapy (+/− chemotherapy) 0%
    Not applicable to my practice 4.2%
Reported opinion on makeup of lymph node metastasis in MPBC
    Mainly the micropapillary component 26.3%
    Mainly the non-micropapillary component 10.2%
    Do not know 63.6%
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